Priority setting at the clinical level: the case of nusinersen and the Norwegian national expert group

Abstract Background Nusinersen is one of an increasing number of new, expensive orphan drugs to receive authorization. These drugs strain public healthcare budgets and challenge principles for resource allocation. Nusinersen was introduced in the Norwegian public healthcare system in 2018. A nationa...

Full description

Bibliographic Details
Main Authors: Morten Magelssen, Magnhild Rasmussen, Sean Wallace, Reidun Førde
Format: Article
Language:English
Published: BMC 2021-05-01
Series:BMC Medical Ethics
Subjects:
Online Access:https://doi.org/10.1186/s12910-021-00623-5